<DOC>
	<DOCNO>NCT02443818</DOCNO>
	<brief_summary>It find people excessive growth one part body normal growth part , may change gene responsible control cell growth . This genetic discovery identify possible treatment overgrowth , call Sirolimus . This pilot study , help investigator prepare large international study , aim determine whether treatment base Sirolimus able stop excessive growth one party body people carry genetic change PIK3CA gene ( phosphatidylinosilol-3-kinase encode gene PIK3CA ) .</brief_summary>
	<brief_title>Sirolimus Effect Hypertrophic Syndromes Related Gene PIK3CA</brief_title>
	<detailed_description>The duration participation 15 month : - Visit screening : blood test , pre-clinical evaluation , urine collection chest X-ray . - First 6 month : participant overgrowth monitor . This step include 2 visit take place University Hospital Dijon : complete clinical evaluation , MRI body part overgrowth Dual-energy X-ray absorptiometry ( DXA ) . - Next 6 month : participant take Sirolimus . This step include 2 visit ( 4 13 week start treatment local hospital ) : blood test , urine collection clinical evaluation . 1 end study visit 6 month treatment take place University Hospital Dijon : blood test , complete clinical evaluation , urine collection , MRI DXA . Participants several blood urine test visit ( 1 2 week start treatment local laboratory ) .</detailed_description>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Postzygotic PIK3CA mutation Age : 365 year Measurable overgrowth , current progression clinical history overgrowth progression Patient clinically stable Presence disability , social cosmetic impairment require treatment patient perspective , Written inform consent form sign dated subject patient 's legal representative Pregnancy lactation Women men reproductive age without effective method contraception ( treatment 12 week sirolimus discontinuation ) Hypersensitivity active substance ( sirolimus ) excipients Impossibility obtain write informed consent form sign subject patient 's legal representative , vulnerable adult Treatment Sirolimus last 4 week trial Personal history malignancy current investigation suspect malignancy Active skin infection require antibiotic antiviral treatment HIV hepatitis B C infection Past history Mycobacterium tuberculosis infection Active pneumopathy Uncontrolled infection Chronic liver disease ( ASAT Alanine amino transf√©rase ( ALAT ) &gt; 3 time upper normal limit ) Stage 3 ( ) chronic renal insufficiency ( eGFR &lt; 60mls/min ) Neutropenia neutrophiles &lt; 1.0 x10^9/L Uncontrolled dyslipidemia Inability attend study visit</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>